Business
VolitionRx Limited Announces Successful Detection of Nucleosomes in Cats
VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces the publication of "Evaluation of plasma nucleosome concentrations and the effect of pre-analytical variables in healthy cats" in BMC Veterinary Research. This is the first study to report the detection of nucleosomes in cats: previously nucleosome levels have been shown to increase in dogs and humans in certain disease states, including cancer.
About this update from Volitionrx Limited
[{"type":"text","content":"Clinical Paper Published in BMC Veterinary Research","length":51,"tagName":"p"},{"type":"text","content":"HENDERSON, Nev., May 19, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces the publication of "Evaluation of plasma nucleosome concentrations and the effect of pre-analytical variables in healthy cats" in BMC Veterinary Research. This is the first study to report the detection of nucleosomes in cats: previously nucleosome levels have been shown to increase in dogs and humans in certain disease states, including cancer.","length":522,"tagName":"p"},{"type":"text","content":"Frederic Wuilque, Vice President, Global Products, said:","length":61,"tagName":"p"},{"type":"text","content":""This is an essential step in the development of Nu.Q® products for cats, our third species. This opens up the potential for cancer screening and monitoring in cats, representing a significant annual commercial opportunity for Volition. There are more than 60 million cats in the U.S. alone, 25% of which are "senior" cats and therefore suitable for an annual check1.","length":382,"tagName":"p"},{"type":"text","content":""This important study confirms that H3.1 nucleosomes can be successfully quantified from blood obtained from healthy cats and presents data regarding an optimal collection and processing protocol. Additionally, it supports the use of EDTA tubes when collecting samples for nucleosome testing in cats.","length":310,"tagName":"p"},{"type":"text","content":""Our first target product is for feline lymphoma, the most common cause of cancer in cats2. We are delighted to have completed the pre-analytics work for feline and confirm that the enrolment for patients for our clinical study for the detection of feline lymphoma has been underway for several months. We look forward to presenting the findings of our Nu.Q® Vet assay in this much needed area upon study completion."","length":433,"tagName":"p"},{"type":"text","content":"About Volition ","length":14,"tagName":"p"},{"type":"text","content":"Volition is a multi-national company focused on advancing the science of epigenetics. Volition is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through e...